SCIOS INC
10-Q, EX-27, 2000-11-13
PHARMACEUTICAL PREPARATIONS
Previous: SCIOS INC, 10-Q, 2000-11-13
Next: REALTY INCOME CORP, 10-Q, 2000-11-13



<TABLE> <S> <C>


<ARTICLE>       5
<LEGEND>



This  schedule  contains  summary  financial   information  extracted  from  the
consolidated   balance  Sheet,   consolidated   statement  of  operations,   and
consolidated statement of cash flows included In the Company's Form 10-Q for the
period ending  September 30, 2000, and is qualified in its entirety By reference
to such financial statements.

</LEGEND>

<MULTIPLIER>                                            1,000

<S>                                                      <C>
<PERIOD-TYPE>                                                    9-MOS
<FISCAL-YEAR-END>                                          Dec-31-2000
<PERIOD-START>                                              Jan-1-2000
<PERIOD-END>                                               Sep-30-2000
<CASH>                                                           3,282
<SECURITIES>                                                    69,849
<RECEIVABLES>                                                    2,960
<ALLOWANCES>                                                         0
<INVENTORY>                                                          0
<CURRENT-ASSETS>                                                25,768
<PP&E>                                                          19,781
<DEPRECIATION>                                                  10,423
<TOTAL-ASSETS>                                                  86,839
<CURRENT-LIABILITIES>                                           28,162
<BONDS>                                                         38,225
<COMMON>                                                            38
                                                0
                                                          0
<OTHER-SE>                                                      20,452
<TOTAL-LIABILITY-AND-EQUITY>                                    86,839
<SALES>                                                         20,287
<TOTAL-REVENUES>                                                30,804
<CGS>                                                           11,935
<TOTAL-COSTS>                                                   60,698
<OTHER-EXPENSES>                                                   418
<LOSS-PROVISION>                                                    0
<INTEREST-EXPENSE>                                               2,928
<INCOME-PRETAX>                                               (30,312)
<INCOME-TAX>                                                         0
<INCOME-CONTINUING>                                           (30,312)
<DISCONTINUED>                                                       0
<EXTRAORDINARY>                                                      0
<CHANGES>                                                            0
<NET-INCOME>                                                  (30,312)
<EPS-BASIC>                                                     (0.80)
<EPS-DILUTED>                                                   (0.80)




</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission